schliessen

Filtern

 

Bibliotheken

An economic analysis of adult hepatitis B vaccination in China

With the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. W... Full description

Journal Title: Vaccine 27 November 2015, Vol.33(48), pp.6831-6839
Main Author: Zheng, Hui
Other Authors: Wang, Fu-Zhen , Zhang, Guo-Min , Cui, Fu-Qiang , Wu, Zhen-Hua , Miao, Ning , Sun, Xiao-Jin , Liang, Xiao-Feng , Li, Li
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0264-410X ; E-ISSN: 1873-2518 ; DOI: 10.1016/j.vaccine.2015.09.011
Link: https://www.sciencedirect.com/science/article/pii/S0264410X15012694
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_vaccine_2015_09_011
title: An economic analysis of adult hepatitis B vaccination in China
format: Article
creator:
  • Zheng, Hui
  • Wang, Fu-Zhen
  • Zhang, Guo-Min
  • Cui, Fu-Qiang
  • Wu, Zhen-Hua
  • Miao, Ning
  • Sun, Xiao-Jin
  • Liang, Xiao-Feng
  • Li, Li
subjects:
  • Hepatitis B
  • Vaccination
  • Adult
  • Medicine
  • Biology
  • Veterinary Medicine
  • Pharmacy, Therapeutics, & Pharmacology
ispartof: Vaccine, 27 November 2015, Vol.33(48), pp.6831-6839
description: With the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. We performed an economic analysis of two different adult HepB vaccination strategies for 21–59-years-olds: vaccination without screening and screening-based vaccination. Cost-benefit analyses were conducted. All 21–59-year-olds were divided into two groups: young adults (ages 21–39) and middle-aged adults (ages 40–59). Costs and benefits were estimated using the direct cost and societal (direct and indirect costs) perspectives. All costs and benefits were adjusted to 2014 US dollars, where future values were discounted at a 3% annual rate. We calculated benefit-cost ratios (BCRs) of the two vaccination strategies for the two different age groups. Sensitivity analyses...
language: eng
source:
identifier: ISSN: 0264-410X ; E-ISSN: 1873-2518 ; DOI: 10.1016/j.vaccine.2015.09.011
fulltext: fulltext
issn:
  • 0264-410X
  • 0264410X
  • 1873-2518
  • 18732518
url: Link


@attributes
ID1915940122
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_vaccine_2015_09_011
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_vaccine_2015_09_011
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18AARKO
19ABBQC
20ABFNM
21ABKYH
22ABMZM
23ABRWV
24ABYKQ
25ACDAQ
26ACIUM
27ACRLP
28AEKER
29AEVXI
30AEXOQ
31AFKWA
32AFTJW
33AFXIZ
34AGEKW
35AGUBO
36AGYEJ
37AIKHN
38AITUG
39AJBFU
40AJOXV
41AJRQY
42AJUYK
43AMFUW
44ANZVX
45BLXMC
46BNPGV
47CJTIS
48EO8
49EO9
50EP2
51EP3
52FDB
53FIRID
54FNPLU
55G-Q
56GBLVA
57J1W
58KOM
59LCYCR
60LUGTX
61O9~
62OAUVE
63OK0
64P-8
65P-9
66PC.
67Q38
68QYZTP
69RPZ
70SCC
71SDF
72SDG
73SDP
74SES
75SNL
76SSH
77SSI
78SSZ
79T5K
80Z5R
81~G-
pqid1785230408
galeid437473532
display
typearticle
titleAn economic analysis of adult hepatitis B vaccination in China
creatorZheng, Hui ; Wang, Fu-Zhen ; Zhang, Guo-Min ; Cui, Fu-Qiang ; Wu, Zhen-Hua ; Miao, Ning ; Sun, Xiao-Jin ; Liang, Xiao-Feng ; Li, Li
ispartofVaccine, 27 November 2015, Vol.33(48), pp.6831-6839
identifier
subjectHepatitis B ; Vaccination ; Adult ; Medicine ; Biology ; Veterinary Medicine ; Pharmacy, Therapeutics, & Pharmacology
descriptionWith the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. We performed an economic analysis of two different adult HepB vaccination strategies for 21–59-years-olds: vaccination without screening and screening-based vaccination. Cost-benefit analyses were conducted. All 21–59-year-olds were divided into two groups: young adults (ages 21–39) and middle-aged adults (ages 40–59). Costs and benefits were estimated using the direct cost and societal (direct and indirect costs) perspectives. All costs and benefits were adjusted to 2014 US dollars, where future values were discounted at a 3% annual rate. We calculated benefit-cost ratios (BCRs) of the two vaccination strategies for the two different age groups. Sensitivity analyses...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X15012694$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Zheng, Hui
1Wang, Fu-Zhen
2Zhang, Guo-Min
3Cui, Fu-Qiang
4Wu, Zhen-Hua
5Miao, Ning
6Sun, Xiao-Jin
7Liang, Xiao-Feng
8Li, Li
titleAn economic analysis of adult hepatitis B vaccination in China
description

With the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. We performed an economic analysis of two different adult HepB vaccination strategies for 21–59-years-olds: vaccination without screening and screening-based vaccination.

Cost-benefit analyses were conducted. All 21–59-year-olds were divided into two groups: young adults (ages 21–39) and middle-aged adults (ages 40–59). Costs and benefits were estimated using the direct cost and societal (direct and indirect costs) perspectives. All costs and benefits were adjusted to 2014 US dollars, where future values were discounted at a 3% annual rate. We calculated benefit-cost ratios (BCRs) of the two vaccination strategies for the two different age groups. Sensitivity analyses...

subject
0Hepatitis B
1Vaccination
2Adult
3Medicine
4Biology
5Veterinary Medicine
6Pharmacy, Therapeutics, & Pharmacology
general
0English
1Elsevier Ltd
210.1016/j.vaccine.2015.09.011
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_vaccine_2015_09_011
issn
00264-410X
10264410X
21873-2518
318732518
rsrctypearticle
creationdate2015
addtitleVaccine
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18AARKO
19ABBQC
20ABFNM
21ABKYH
22ABMZM
23ABRWV
24ABYKQ
25ACDAQ
26ACIUM
27ACRLP
28AEKER
29AEVXI
30AEXOQ
31AFKWA
32AFTJW
33AFXIZ
34AGEKW
35AGUBO
36AGYEJ
37AIKHN
38AITUG
39AJBFU
40AJOXV
41AJRQY
42AJUYK
43AMFUW
44ANZVX
45BLXMC
46BNPGV
47CJTIS
48EO8
49EO9
50EP2
51EP3
52FDB
53FIRID
54FNPLU
55G-Q
56GBLVA
57J1W
58KOM
59LCYCR
60LUGTX
61O9~
62OAUVE
63OK0
64P-8
65P-9
66PC.
67Q38
68QYZTP
69RPZ
70SCC
71SDF
72SDG
73SDP
74SES
75SNL
76SSH
77SSI
78SSZ
79T5K
80Z5R
81~G-
startdate20151127
enddate20151127
lsr40Vaccine, 27 November 2015, Vol.33 (48), pp.6831-6839
doi10.1016/j.vaccine.2015.09.011
citationpf 6831 pt 6839 vol 33 issue 48
lsr30VSR-Enriched:[pqid, galeid]
sort
titleAn economic analysis of adult hepatitis B vaccination in China
authorZheng, Hui ; Wang, Fu-Zhen ; Zhang, Guo-Min ; Cui, Fu-Qiang ; Wu, Zhen-Hua ; Miao, Ning ; Sun, Xiao-Jin ; Liang, Xiao-Feng ; Li, Li
creationdate20151127
lso0120151127
facets
frbrgroupid8719357383808090178
frbrtype5
newrecords20190904
languageeng
topic
0Hepatitis B
1Vaccination
2Adult
3Medicine
4Biology
5Veterinary Medicine
6Pharmacy, Therapeutics, & Pharmacology
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zheng, Hui
1Wang, Fu-Zhen
2Zhang, Guo-Min
3Cui, Fu-Qiang
4Wu, Zhen-Hua
5Miao, Ning
6Sun, Xiao-Jin
7Liang, Xiao-Feng
8Li, Li
jtitleVaccine
creationdate2015
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zheng
1Wang
2Zhang
3Cui
4Wu
5Miao
6Sun
7Liang
8Li
aufirst
0Hui
1Fu-Zhen
2Guo-Min
3Fu-Qiang
4Zhen-Hua
5Ning
6Xiao-Jin
7Xiao-Feng
8Li
auinitH
auinit1H
au
0Zheng, Hui
1Wang, Fu-Zhen
2Zhang, Guo-Min
3Cui, Fu-Qiang
4Wu, Zhen-Hua
5Miao, Ning
6Sun, Xiao-Jin
7Liang, Xiao-Feng
8Li, Li
atitleAn economic analysis of adult hepatitis B vaccination in China
jtitleVaccine
risdate20151127
volume33
issue48
spage6831
epage6839
pages6831-6839
issn0264-410X
eissn1873-2518
formatjournal
genrearticle
ristypeJOUR
abstract

With the universal infant hepatitis B vaccination (HepB) program, China has made remarkable achievements to prevent and control hepatitis B. In order to further reduce hepatitis B virus (HBV) infection, the Chinese government is considering implementing a widespread adult HBV vaccination campaign. We performed an economic analysis of two different adult HepB vaccination strategies for 21–59-years-olds: vaccination without screening and screening-based vaccination.

Cost-benefit analyses were conducted. All 21–59-year-olds were divided into two groups: young adults (ages 21–39) and middle-aged adults (ages 40–59). Costs and benefits were estimated using the direct cost and societal (direct and indirect costs) perspectives. All costs and benefits were adjusted to 2014 US dollars, where future values were discounted at a 3% annual rate. We calculated benefit-cost ratios (BCRs) of the two vaccination strategies for the two different age groups. Sensitivity analyses...

pubElsevier Ltd
doi10.1016/j.vaccine.2015.09.011
lad01Vaccine
date2015-11-27